GXO Logistics Inc vs Smith & Nephew plc — how do they compare? GXO Logistics Inc trades at $46.56 (market cap $5.32B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 2.1× GXO Logistics Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and Smith & Nephew plc for 121 Days on average.
| GXO | SNN | |
|---|---|---|
Market Cap | $5.32B | $11.10B |
Volume | 1,255,816 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $65.59 | $37.17 |
52-Week Low | $44.17 | $26.42 |
Typical Hold Time | 28 Days | 121 Days |
Enterprise Value | $10.67B | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
GXO trades at $46.56, up 1.24% today, with a neutral technical signal and bearish moving average trend. The company reported Q2 2026 EPS of $0.59, beating estimates, and maintains strong analyst support with an 88.89% buy rating. Recent news highlights strategic partnerships with Columbia Sportswear and expansion in aerospace & defense, signaling growth initiatives. Revenue for 2025 was $13.18 billion, with a net income margin of 0.96%, though profitability remains modest.
The outlook is positive, driven by analyst consensus price target of $66.67 and improving industry prospects. Key opportunities include operational efficiency gains from new labor management systems and sector tailwinds. Risks involve stagnant margins and competitive pressures, requiring close monitoring of execution on growth targets to justify current valuations.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Trailing returns across standard periods
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →